Developer docs
API playgroundTry for free, no card

Search company profiles

Tarveda Therapeutics

Full company profile

uuid0002dmi

Namestring
Tarveda Therapeutics
Legal namestring
Tarveda Therapeutics, Inc.
Websiteurl
tarvedatx.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Tarveda Therapeutics is a clinical-stage biopharmaceutical company developing miniature drug conjugates — a proprietary class of targeted therapeutics that pairs a tumor-targeting ligand with a cytotoxic payload engineered to concentrate drug activity in solid tumor tissue while limiting systemic exposure. Founded in 2012 in Watertown, Massachusetts by Stephen J. Lippard (a recognized authority in platinum-based anticancer chemistry), the company is led by Chairman Drew Fromkin, Chief Scientific Officer Mark Bilodeau, and Chief Medical Officer Jeffrey Bloss, with corporate development supported by EVP of Strategy Sudha Kadiyala. The platform is structurally applicable across multiple solid tumor indications, which supports a pipeline-program strategy rather than a single-asset focus.

The business model is purely R&D-driven and pre-revenue. Tarveda has no marketed product, no disclosed licensing revenue, no pricing model, and no commercial customer base. Value creation depends entirely on advancing clinical milestones, de-risking the pipeline, and ultimately enabling either a strategic exit (acquisition or partnership with a large pharmaceutical company) or further equity financing. To date the company has raised approximately $148 million across nine disclosed rounds between 2012 and 2021, with backing from tier-1 biotech investors Flagship Pioneering, New Enterprise Associates (NEA), Novo Holdings, Versant Ventures, and ND Capital. The largest single rounds were a $38 million Series D in January 2016 (led by Novo Holdings) and a $30 million Series E in February 2017 (led by Versant Ventures); subsequent raises have been materially smaller, and the most recent disclosed round is a ~$6 million insider-heavy SEC Form D offering filed in September 2021 under Rule 506(b).

The company's operating footprint is a single headquarters in Watertown, Massachusetts, with a headcount of 11–50 employees. The corporate website (tarvedatx.com) currently displays Indonesian-language online-gambling content rather than corporate material, which strongly indicates the domain is no longer actively maintained and is a soft negative signal about current operational health. Geographic markets served are limited to the United States. There is no disclosed regulatory approval, no FDA-cleared product, and no public listing.

Short descriptiontext

Tarveda Therapeutics is a clinical-stage biopharmaceutical company developing miniature drug conjugates — targeted therapies combining a ligand with a cytotoxic payload — for solid tumors. Founded in 2012 in Watertown, Massachusetts, the company is venture-backed and pre-revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
miniature drug conjugates, solid tumor therapeutics, oncology drug development, targeted cancer therapy, conjugate drug platform
Industry1 code
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Targeted Oncology Therapeutics
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tarveda Therapeutics is a developer of miniature drug conjugates — a class of targeted therapeutics — designed for the treatment of patients with a wide range of solid tumors. The company's pipeline leverages a proprietary conjugate platform aimed at delivering potent cytotoxic agents selectively to solid tumor tissue. Activities span discovery, preclinical, and clinical development of these oncology candidates.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Miniature Drug Conjugate Platform
CategoryTargeted Oncology Therapeutics
Description

Proprietary platform of miniature drug conjugates — targeted therapeutics combining a targeting ligand, linker, and cytotoxic warhead — engineered for the treatment of patients with a wide range of solid tumors.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer in antibody-drug conjugates for solid tumors, now part of AbbVie. Directly comparable to Tarveda as a developer of targeted cytotoxic conjugates for oncology indications.

TypeDirect peer
Description

Clinical-stage ADC developer focused on solid tumors with proprietary linker and payload platforms. Directly comparable as a small-cap, clinical-stage oncology conjugate developer.

TypeDirect peer
Description

Developer of Probody therapeutics, conditionally activated antibody-based agents for solid tumors. Comparable as a clinical-stage oncology platform using engineered protein constructs to improve tumor selectivity.

TypeDirect peer
Description

Late-stage ADC developer with approved and clinical-stage oncology assets. Comparable as a focused ADC company developing targeted cytotoxic conjugates for solid and hematologic tumors.

TypeDirect peer
Description

Developer of immune-stimulating antibody conjugates for solid tumors. Comparable as a small-cap oncology platform company using conjugate chemistry to drive tumor-targeted therapeutics.

TypeDirect peer
Description

ADC developer using proprietary amanitin payload technology for solid tumors. Comparable as a clinical-stage company building novel cytotoxic conjugate platforms for oncology.

TypeDirect peer
Description

Clinical-stage developer of ADC and immuno-oncology candidates for solid tumors. Comparable as a venture-backed oncology platform company developing targeted therapeutics.

8Mythic Therapeutics
TypeEmerging player
Description

Emerging ADC developer focused on solid tumors using protein-engineering approaches. Comparable as an early-stage player pursuing next-generation conjugate formats, similar to Tarveda's miniaturized approach.

TypeEmerging player
Description

European preclinical-stage ADC developer with proprietary linker chemistry. Comparable as an emerging player in next-generation targeted oncology conjugates.

TypeBroad incumbent
Description

Large pharma with significant ADC and solid-tumor oncology franchises (e.g., through Seagen acquisition). Relevant as a potential acquirer or BD partner for clinical-stage oncology conjugate developers like Tarveda.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tarveda Therapeutics

Targeted Oncology Therapeuticstarvedatx.com

Tarveda Therapeutics is a clinical-stage biopharmaceutical company developing miniature drug conjugates — targeted therapies combining a ligand with a cytotoxic payload — for solid tumors. Founded in 2012 in Watertown, Massachusetts, the company is venture-backed and pre-revenue.

What Tarveda Therapeutics does

Tarveda Therapeutics is a clinical-stage biopharmaceutical company developing miniature drug conjugates — a proprietary class of targeted therapeutics that pairs a tumor-targeting ligand with a cytotoxic payload engineered to concentrate drug activity in solid tumor tissue while limiting systemic exposure. Founded in 2012 in Watertown, Massachusetts by Stephen J. Lippard (a recognized authority in platinum-based anticancer chemistry), the company is led by Chairman Drew Fromkin, Chief Scientific Officer Mark Bilodeau, and Chief Medical Officer Jeffrey Bloss, with corporate development supported by EVP of Strategy Sudha Kadiyala. The platform is structurally applicable across multiple solid tumor indications, which supports a pipeline-program strategy rather than a single-asset focus.

The business model is purely R&D-driven and pre-revenue. Tarveda has no marketed product, no disclosed licensing revenue, no pricing model, and no commercial customer base. Value creation depends entirely on advancing clinical milestones, de-risking the pipeline, and ultimately enabling either a strategic exit (acquisition or partnership with a large pharmaceutical company) or further equity financing. To date the company has raised approximately $148 million across nine disclosed rounds between 2012 and 2021, with backing from tier-1 biotech investors Flagship Pioneering, New Enterprise Associates (NEA), Novo Holdings, Versant Ventures, and ND Capital. The largest single rounds were a $38 million Series D in January 2016 (led by Novo Holdings) and a $30 million Series E in February 2017 (led by Versant Ventures); subsequent raises have been materially smaller, and the most recent disclosed round is a ~$6 million insider-heavy SEC Form D offering filed in September 2021 under Rule 506(b).

The company's operating footprint is a single headquarters in Watertown, Massachusetts, with a headcount of 11–50 employees. The corporate website (tarvedatx.com) currently displays Indonesian-language online-gambling content rather than corporate material, which strongly indicates the domain is no longer actively maintained and is a soft negative signal about current operational health. Geographic markets served are limited to the United States. There is no disclosed regulatory approval, no FDA-cleared product, and no public listing.

Tarveda Therapeutics firmographics

Firmographics
Name
Tarveda Therapeutics
Legal name
Tarveda Therapeutics, Inc.
Website
https://tarvedatx.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
Tarveda Therapeutics is a clinical-stage biopharmaceutical company developing miniature drug conjugates — targeted therapies combining a ligand with a cytotoxic payload — for solid tumors. Founded in 2012 in Watertown, Massachusetts, the company is venture-backed and pre-revenue.
Ownership category
akta.pro rank

Tarveda Therapeutics industry classification

Industry
Product category
Targeted Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Miniature drug conjugates
  • Solid tumor therapeutics
  • Oncology drug development
  • Targeted cancer therapy
  • Conjugate drug platform

Where Tarveda Therapeutics is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Tarveda Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Tarveda Therapeutics product offering

Product offering

Core offering

Tarveda Therapeutics is a developer of miniature drug conjugates — a class of targeted therapeutics — designed for the treatment of patients with a wide range of solid tumors. The company's pipeline leverages a proprietary conjugate platform aimed at delivering potent cytotoxic agents selectively to solid tumor tissue. Activities span discovery, preclinical, and clinical development of these oncology candidates.

Differentiator

Problem solved

Functional benefit

Products and services

  • Miniature Drug Conjugate Platform Proprietary platform of miniature drug conjugates — targeted therapeutics combining a targeting ligand, linker, and cytotoxic warhead — engineered for the treatment of patients with a wide range of solid tumors.

Companies that use Tarveda Therapeutics

Customer profile

Ideal customer profiles1 record

Tarveda Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Tarveda Therapeutics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Tarveda Therapeutics competitors and assessment

Company assessment

Direct peers

  • ImmunoGen: Pioneer in antibody-drug conjugates for solid tumors, now part of AbbVie. Directly comparable to Tarveda as a developer of targeted cytotoxic conjugates for oncology indications.
  • Mersana Therapeutics: Clinical-stage ADC developer focused on solid tumors with proprietary linker and payload platforms. Directly comparable as a small-cap, clinical-stage oncology conjugate developer.
  • CytomX Therapeutics: Developer of Probody therapeutics, conditionally activated antibody-based agents for solid tumors. Comparable as a clinical-stage oncology platform using engineered protein constructs to improve tumor selectivity.
  • ADC Therapeutics: Late-stage ADC developer with approved and clinical-stage oncology assets. Comparable as a focused ADC company developing targeted cytotoxic conjugates for solid and hematologic tumors.
  • Bolt Biotherapeutics: Developer of immune-stimulating antibody conjugates for solid tumors. Comparable as a small-cap oncology platform company using conjugate chemistry to drive tumor-targeted therapeutics.
  • Heidelberg Pharma: ADC developer using proprietary amanitin payload technology for solid tumors. Comparable as a clinical-stage company building novel cytotoxic conjugate platforms for oncology.
  • Pyxis Oncology: Clinical-stage developer of ADC and immuno-oncology candidates for solid tumors. Comparable as a venture-backed oncology platform company developing targeted therapeutics.

Emerging players

  • Mythic Therapeutics: Emerging ADC developer focused on solid tumors using protein-engineering approaches. Comparable as an early-stage player pursuing next-generation conjugate formats, similar to Tarveda's miniaturized approach.
  • Tubulis: European preclinical-stage ADC developer with proprietary linker chemistry. Comparable as an emerging player in next-generation targeted oncology conjugates.

Broad incumbents

  • Pfizer: Large pharma with significant ADC and solid-tumor oncology franchises (e.g., through Seagen acquisition). Relevant as a potential acquirer or BD partner for clinical-stage oncology conjugate developers like Tarveda.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Tarveda Therapeutics social profiles

Digital presence

Tarveda Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tarveda Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Tarveda Therapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tarveda Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tarveda Therapeutics

What does Tarveda Therapeutics do?

Tarveda Therapeutics is a developer of miniature drug conjugates — a class of targeted therapeutics — designed for the treatment of patients with a wide range of solid tumors. The company's pipeline leverages a proprietary conjugate platform aimed at delivering potent cytotoxic agents selectively to solid tumor tissue. Activities span discovery, preclinical, and clinical development of these oncology candidates.

Is Tarveda Therapeutics a public or private company?

Tarveda Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Tarveda Therapeutics founded?

Tarveda Therapeutics was founded in 2011. It employs 1 to 10 people.

Where is Tarveda Therapeutics based?

Tarveda Therapeutics is headquartered in Watertown, United States, in the North America region.

Who are Tarveda Therapeutics's main competitors?

Direct peers on record are ImmunoGen, Mersana Therapeutics, CytomX Therapeutics, ADC Therapeutics, Bolt Biotherapeutics, Heidelberg Pharma and Pyxis Oncology. Emerging players are Mythic Therapeutics and Tubulis. Pfizer is listed as a broad incumbent.

Does Tarveda Therapeutics have an API?

No public API is recorded for Tarveda Therapeutics.

What industry is Tarveda Therapeutics in?

Tarveda Therapeutics's product category is Targeted Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DTarveda Therapeutics, Inc. filed a Form D with the SEC to report an exempt offering of securities under Rule 506(b). The company disclosed a total offering amount of $5,999,999 USD, with all funds already sold to one investor. The filing was signed by CEO Brian Roberts on September 27, 2021.GlobeNewswireOrganovo Holdings Founder Calls on Board of Directors to Accept Stockholders’ Opposition to the Illogical Merger With Tarveda TherapeuticsOrganovo founder Keith Murphy urged the board to accept stockholder opposition to the proposed merger with Tarveda Therapeutics, citing the company's limited cash and sparse prospects. He called for incumbent directors to resign if they ignore investor feedback and urged the board not to adjourn the April 7 special meeting.GlobeNewswireOrganovo Holdings Founder Issues Letter Regarding Alternative Paths to Illogical Merger With Tarveda Therapeutics to StockholdersOrganovo founder Keith Murphy issued a letter to stockholders opposing the proposed merger with Tarveda Therapeutics, citing Tarveda's weak financial position and lack of synergies. He plans to vote against the merger but for the reverse stock split, urging the board to pursue bioprinting opportunities or a better combination partner.GlobeNewswireOrganovo Founder Issues Letter to Stockholders Regarding Major Missteps and Misjudgment of the Company’s Board of DirectorsOrganovo founder Keith Murphy issued a letter to stockholders opposing the proposed merger with Tarveda Therapeutics, citing the board's poor track record since 2017. He highlighted the board's retention of a failing CEO and lack of a therapeutic tissue pipeline, and stated he will vote against the merger.PR Newswire101 Antibody-Drug Conjugate Experts to Present at the Industry's Longest Standing & Most Comprehensive Antibody-Drug Conjugate ConferenceThe 8th annual World ADC San Diego conference is taking place September 20-22, 2017, in San Diego, California, expecting record attendance of over 650 participants from pharmaceutical companies, biotechs, academia, and industry suppliers. The event will feature 101 expert speakers presenting on antibody-drug conjugate (ADC) development topics including novel payloads, linker technologies, and clinical programs from companies such as Femtogenix, Eisai, Heidelberg Pharma, Tarveda Therapeutics, and Seattle Genetics. The conference also hosts the World ADC Awards recognizing innovation and leadership in the global ADC industry.FinSMEsTarveda Therapeutics Raises $30M in Series D FinancingTarveda Therapeutics raised $30M in Series D financing led by Versant Ventures, with participation from existing investors. The company will use the funds to advance its Pentarin platform, including completing Phase I studies of PEN-221 and initiating Phase 2A studies. Guido Magni will join the board.MedCity NewsSend in the Pentarins: Tarveda raises $30M Series DTarveda Therapeutics raised $30 million in a Series D led by Versant Ventures, with participation from existing investors. The company will use the funds to complete Phase I dose-escalation studies for its lead drug PEN-221 and further develop Pentarin candidates. The company plans a Phase 2A study if the Phase I is successful.GlobeNewswireMadrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology PlatformMadrigal Pharmaceuticals and Tarveda Therapeutics announced an exclusive worldwide license agreement for Madrigal's HSP90 drug conjugate platform, including lead candidate PEN-866. Madrigal will receive an upfront payment and up to $163 million in contingent milestone payments, with Tarveda responsible for development costs. PEN-866 is scheduled to begin clinical trials in 2017.PE HubTarveda Therapeutics scores $38 mln Series CTarveda Therapeutics raised $38 million in Series C funding led by Novo A/S and New Enterprise Associates. The round was led by Novo and NEA, with other investors including Flagship Ventures, NanoDimension, and Eminent Venture Capital. Nilesh Kumar and Dr. Frank Torti joined the board, and Drew Fromkin was appointed interim chairman.VC News DailyBlend Therapeutics Secures $38M in Series CTarveda Therapeutics, Inc., formerly Blend Therapeutics, announced it secured $38 million in Series C financing co-led by Novo A/S and New Enterprise Associates (NEA). The funding will advance the company's Pentarin drug pipeline, specifically supporting Phase 1 clinical studies for lead candidate PEN-221 targeting neuroendocrine cancers and small cell lung cancer, expected to begin in mid-2016. Concurrent with the financing, the company spun off its platinum drug candidate BTP-114 into a newly formed independent company, Placon Therapeutics.